The Pharmaceutical Journal
Vol 274 No 7339 p263
5 March 2005

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Supply of MS drug

Supply of natalizumab, a multiple sclerosis drug, has been suspended by its manufacturers. The move follows reports of two serious adverse events in patients taking part in clinical trials. The events involve one fatal, confirmed case and one suspected case of progressive multifocal leukoencephalopathy.